XML 49 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Party Transactions (Details Narrative)
 1 Months Ended 12 Months Ended
Sep. 09, 2016
USD ($)
$ / shares
shares
Feb. 02, 2016
USD ($)
$ / shares
shares
May 01, 2015
USD ($)
Installment
Sep. 25, 2014
USD ($)
Number
Dec. 31, 2016
USD ($)
$ / shares
shares
Dec. 31, 2015
USD ($)
Nov. 01, 2015
USD ($)
Common stock shares reserved under stock option plan | shares         19,595,000    
Accounts payable         $ 33,290 $ 30,095  
Research and development expense         $ 309,503 281,218  
Exercise Price | $ / shares         $ 1.42    
Charitable Gift Agreement [Member]              
Donation to the University             $ 83,000
Charitable Grant Agreement [Member]              
Donation to the University       $ 75,000      
Donation periodic payment       $ 9,375      
Number of installments | Number       8      
Dr. Gerlach [Member]              
Compensation expense for services         $ 42,480 36,720  
Joseph Sierchio [Member]              
Annual retainer payable         $ 6,000    
Common stock shares reserved under stock option plan | shares         50,000    
Exercise price | $ / shares         $ 1.91    
Legal fees         $ 168,775 101,700  
Accounts payable           8,322  
Kenneth Kirkland [Member]              
Annual retainer payable         $ 6,000    
Common stock shares reserved under stock option plan | shares         50,000    
Exercise price | $ / shares         $ 1.91    
Option agreement [Member] | Dr. Gerlach [Member]              
Number of installments | Installment     4        
Fees payable under agreement     $ 24,000        
Due to related party periodic payment     6,000        
Research and development expense     $ 24,000        
KCC [Member] | Loan agreement [Member]              
Convertible debt financing, Maximum amount $ 900,000            
Convertible debt financing, Loan received 700,000            
Convertible debt financing, Remaining amount $ 200,000            
Interest rate 7.00%            
Maturity date Dec. 31, 2017            
Debt instrument conversion feature

(i) $1.54, or the closing price of the Company’s common stock on the day prior to the issuance of the Note or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23

            
Debt instrument floor price | $ / shares $ 1.23            
KCC [Member] | Series B Warrant [Member]              
Debt conversion converted instrument shares issued | shares   2,173,913          
Exercise Price | $ / shares   $ 0.46          
Proceeds from issuance of common stock   $ 1,000,000          
KCC [Member] | Series E Warrant [Member] | Loan agreement [Member]              
Common stock shares reserved under stock option plan | shares 584,416            
Debt instrument conversion feature

(i) $1.54, the closing price of the Company’s common stock on the day prior to issuance of the Series E Warrant; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant

            
Warrant expiration period 5 years            
StemCell Systems [Member]              
Incurred expenses         $ 184,517 $ 194,336  
Satterlee Stephens LLP [Member]              
Accounts payable         $ 11,750